pyridoxamine has been researched along with Diabetic Nephropathies in 31 studies
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the current manuscript, we studied the effect of pyridoxamine (PM) on protein glycation, oxidative stress, interleukin-1α (IL-1α), IL-6, C-reactive protein (CRP), gene expression of tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) in relation to microalbuminuria and kidney functions in a model of alloxan-induced diabetic rats." | 7.79 | Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. ( Elseweidy, MM; Elswefy, SE; Younis, NN; Zaghloul, MS, 2013) |
| " Thiamine was found to be beneficial for reduction in albuminuria in a single study; however, there was lack of any improvement in kidney function or blood pressure following the use of vitamin B preparations used alone or in combination." | 4.91 | Vitamin B and its derivatives for diabetic kidney disease. ( Gor, D; Rangoonwala, AN; Raval, AD; Thakker, D; Walia, R, 2015) |
| " In the current manuscript, we studied the effect of pyridoxamine (PM) on protein glycation, oxidative stress, interleukin-1α (IL-1α), IL-6, C-reactive protein (CRP), gene expression of tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) in relation to microalbuminuria and kidney functions in a model of alloxan-induced diabetic rats." | 3.79 | Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. ( Elseweidy, MM; Elswefy, SE; Younis, NN; Zaghloul, MS, 2013) |
| "The pyridoxamine pilot study was designed to test entry criteria and outcomes." | 2.80 | Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study. ( Broome, BR; Dwyer, JP; Fox, JW; Greco, BA; Greene, LE; Lewis, JB; Packham, D; Peterson, R; Sika, M; Umanath, K, 2015) |
| "Treatments of diabetic nephropathy (DN) delay the onset of end-stage renal disease." | 2.73 | Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. ( Bolton, WK; Degenhardt, TP; Khalifah, RG; McGill, JB; Schotzinger, RJ; Williams, ME, 2007) |
| "Treatment with pyridoxamine (an inhibitor of advanced glycation end-products) may represent a strategy to counter these injurious pathways." | 2.50 | Have we reached the limits for the treatment of diabetic nephropathy? ( Goldsmith, DJ; Hajhosseiny, R; Jivraj, N; Khavandi, K; Malik, RA; Mashayekhi, S, 2014) |
| "Diabetic nephropathy is a leading cause of end-stage renal disease worldwide." | 2.50 | [Diabetic nephropathy: emerging treatments]. ( Cazenave, M; Gauthier, M; Gueutin, V; Izzedine, H, 2014) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease, and both the incidence and prevalence of diabetic nephropathy continue to increase." | 2.46 | Potential new therapeutic agents for diabetic kidney disease. ( Bolton, WK; Turgut, F, 2010) |
| "Pyridoxamine is an inhibitor of advanced glycation end-product (AGE) formation derived from vitamin B(6)." | 2.43 | The next generation of diabetic nephropathy therapies: an update. ( Tuttle, KR; Williams, ME, 2005) |
| "Pyridoxamine is an efficient AGE inhibitor in experimental diabetes." | 2.43 | New potential agents in treating diabetic kidney disease: the fourth act. ( Williams, ME, 2006) |
| "The role of AGEs in diabetic nephropathy has been established by years of basic research." | 2.42 | Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. ( Williams, ME, 2004) |
| "Pyridoxamine (PM) is a promising drug candidate for treatment of diabetic nephropathy." | 1.35 | Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. ( Chetyrkin, SV; Hudson, BG; Serianni, AS; Voziyan, PA; Zhang, W, 2008) |
| "A mouse model for diabetic nephropathy that encompasses the salient features of this disease in the kidney is not available." | 1.34 | Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. ( Grahovac, G; Kalluri, R; Sugimoto, H; Zeisberg, M, 2007) |
| "Pyridoxamine treatment, as single therapy, decreased the progression of albuminuria and glomerular lesions." | 1.33 | Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. ( Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (61.29) | 29.6817 |
| 2010's | 12 (38.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiazza, F | 1 |
| Cento, AS | 1 |
| Collotta, D | 1 |
| Nigro, D | 1 |
| Rosa, G | 1 |
| Baratta, F | 1 |
| Bitonto, V | 1 |
| Cutrin, JC | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Collino, M | 1 |
| Elseweidy, MM | 1 |
| Elswefy, SE | 1 |
| Younis, NN | 1 |
| Zaghloul, MS | 1 |
| Hajhosseiny, R | 1 |
| Khavandi, K | 1 |
| Jivraj, N | 1 |
| Mashayekhi, S | 1 |
| Goldsmith, DJ | 1 |
| Malik, RA | 1 |
| Alicic, RZ | 1 |
| Tuttle, KR | 2 |
| Gueutin, V | 1 |
| Gauthier, M | 1 |
| Cazenave, M | 1 |
| Izzedine, H | 1 |
| Dwyer, JP | 1 |
| Greco, BA | 1 |
| Umanath, K | 1 |
| Packham, D | 1 |
| Fox, JW | 1 |
| Peterson, R | 1 |
| Broome, BR | 1 |
| Greene, LE | 1 |
| Sika, M | 1 |
| Lewis, JB | 2 |
| Raval, AD | 1 |
| Thakker, D | 1 |
| Rangoonwala, AN | 1 |
| Gor, D | 1 |
| Walia, R | 1 |
| Pena-Polanco, JE | 1 |
| Fried, LF | 1 |
| Breyer, MD | 1 |
| Susztak, K | 1 |
| Burney, BO | 1 |
| Kalaitzidis, RG | 1 |
| Bakris, GL | 1 |
| Turgut, F | 1 |
| Bolton, WK | 2 |
| Lewis, EJ | 1 |
| Greene, T | 1 |
| Spitalewiz, S | 1 |
| Blumenthal, S | 1 |
| Berl, T | 1 |
| Hunsicker, LG | 1 |
| Pohl, MA | 1 |
| Rohde, RD | 1 |
| Raz, I | 1 |
| Yerushalmy, Y | 1 |
| Yagil, Y | 1 |
| Herskovits, T | 1 |
| Atkins, RC | 1 |
| Reutens, AT | 1 |
| Packham, DK | 1 |
| Chen, JL | 1 |
| Francis, J | 1 |
| Metz, TO | 2 |
| Alderson, NL | 3 |
| Thorpe, SR | 3 |
| Baynes, JW | 3 |
| Del Vecchio, L | 1 |
| Ishikawa, N | 1 |
| Miyata, T | 1 |
| Kurokawa, K | 1 |
| Chachich, ME | 1 |
| Frizzell, N | 1 |
| Canning, P | 1 |
| Januszewski, AS | 1 |
| Youssef, NN | 1 |
| Stitt, AW | 1 |
| Williams, ME | 4 |
| Giannoukakis, N | 1 |
| Coughlan, MT | 1 |
| Cooper, ME | 1 |
| Forbes, JM | 1 |
| Pedchenko, VK | 1 |
| Chetyrkin, SV | 2 |
| Chuang, P | 1 |
| Ham, AJ | 1 |
| Saleem, MA | 1 |
| Mathieson, PW | 1 |
| Hudson, BG | 2 |
| Voziyan, PA | 2 |
| Zheng, F | 1 |
| Zeng, YJ | 1 |
| Plati, AR | 1 |
| Elliot, SJ | 1 |
| Berho, M | 1 |
| Potier, M | 1 |
| Striker, LJ | 1 |
| Striker, GE | 1 |
| Tanimoto, M | 1 |
| Gohda, T | 1 |
| Kaneko, S | 1 |
| Hagiwara, S | 1 |
| Murakoshi, M | 1 |
| Aoki, T | 1 |
| Yamada, K | 1 |
| Ito, T | 1 |
| Matsumoto, M | 1 |
| Horikoshi, S | 1 |
| Tomino, Y | 1 |
| Nakamura, S | 1 |
| Li, H | 1 |
| Adijiang, A | 1 |
| Pischetsrieder, M | 1 |
| Niwa, T | 1 |
| Sugimoto, H | 1 |
| Grahovac, G | 1 |
| Zeisberg, M | 1 |
| Kalluri, R | 1 |
| Khalifah, RG | 1 |
| Degenhardt, TP | 2 |
| Schotzinger, RJ | 1 |
| McGill, JB | 1 |
| Zhang, W | 1 |
| Serianni, AS | 1 |
| Swaminathan, S | 1 |
| Shah, SV | 1 |
| Arrington, DD | 1 |
| Beattie, RJ | 1 |
| Basgen, JM | 1 |
| Steffes, MW | 1 |
16 reviews available for pyridoxamine and Diabetic Nephropathies
| Article | Year |
|---|---|
Have we reached the limits for the treatment of diabetic nephropathy?
Topics: Animals; Diabetic Nephropathies; Humans; Oleanolic Acid; Pyridoxamine; Renin-Angiotensin System; Vit | 2014 |
Novel therapies for diabetic kidney disease.
Topics: Acetylcysteine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; | 2014 |
[Diabetic nephropathy: emerging treatments].
Topics: Adrenocorticotropic Hormone; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoc | 2014 |
Vitamin B and its derivatives for diabetic kidney disease.
Topics: Albuminuria; Diabetic Nephropathies; Folic Acid; Humans; Pyridoxamine; Randomized Controlled Trials | 2015 |
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease.
Topics: Allopurinol; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bicarbonate | 2016 |
Developing Treatments for Chronic Kidney Disease in the 21st Century.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents | 2016 |
Novel therapies of diabetic nephropathy.
Topics: Amides; Animals; Diabetic Nephropathies; Fumarates; Humans; Indoles; Maleimides; Pyridoxamine; Super | 2009 |
Potential new therapeutic agents for diabetic kidney disease.
Topics: Amides; Animals; Clinical Trials as Topic; Connective Tissue Growth Factor; Diabetic Nephropathies; | 2010 |
Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
Topics: Animals; Diabetic Nephropathies; Enzyme Inhibitors; Glycation End Products, Advanced; Humans; Lipid | 2003 |
[Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyp | 2004 |
Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
Topics: Diabetic Nephropathies; Enzyme Inhibitors; Glycation End Products, Advanced; Guanidines; Humans; Mod | 2004 |
The next generation of diabetic nephropathy therapies: an update.
Topics: Animals; Diabetic Nephropathies; Disease Progression; Enzyme Inhibitors; Glycation End Products, Adv | 2005 |
Pyridoxamine (BioStratum).
Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Glycation End Products, Advanced; Humans; | 2005 |
Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
Topics: Animals; Diabetic Nephropathies; Disease Models, Animal; Glycation End Products, Advanced; Guanidine | 2005 |
New potential agents in treating diabetic kidney disease: the fourth act.
Topics: Animals; Diabetic Nephropathies; Drugs, Investigational; Glycation End Products, Advanced; Glycosami | 2006 |
Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease.
Topics: Biomarkers; Chronic Disease; Diabetic Nephropathies; Disease Progression; Drugs, Investigational; Gl | 2008 |
3 trials available for pyridoxamine and Diabetic Nephropathies
| Article | Year |
|---|---|
Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antioxidants; Creatinine; D | 2015 |
Pyridorin in type 2 diabetic nephropathy.
Topics: Aged; Creatinine; Cystatin C; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method | 2012 |
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
Topics: Adolescent; Adult; Aged; Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ne | 2007 |
12 other studies available for pyridoxamine and Diabetic Nephropathies
| Article | Year |
|---|---|
Protective Effects of Pyridoxamine Supplementation in the Early Stages of Diet-Induced Kidney Dysfunction.
Topics: Albumins; Animals; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2017 |
Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
Topics: Albuminuria; Alloxan; Animals; C-Reactive Protein; Cytokines; Diabetes Mellitus, Experimental; Diabe | 2013 |
Pyridoxamine, advanced glycation inhibition, and diabetic nephropathy.
Topics: Diabetic Nephropathies; Female; Humans; Male; Pyridoxamine | 2012 |
American society of nephrology-36th annual meeting and renal week 2003.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Calcium; Diabetic Nephr | 2004 |
Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, E | 2004 |
Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy.
Topics: Aldehydes; Arginine; Binding Sites; Cell Adhesion; Cell Physiological Phenomena; Collagen Type IV; D | 2005 |
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepine | 2006 |
Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Glycat | 2007 |
Pyridoxal phosphate prevents progression of diabetic nephropathy.
Topics: Administration, Oral; Animals; Diabetic Nephropathies; Female; Fibronectins; Glycation End Products, | 2007 |
Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Diabetic Nephropathies; Disease | 2007 |
Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine.
Topics: Animals; Cattle; Cell Adhesion; Cell Line, Transformed; Collagen Type IV; Deoxyglucose; Diabetic Nep | 2008 |
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
Topics: Animals; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Fem | 2002 |